Biophytis S.A.
Clinical-stage biotech developing therapeutics for age-related degenerative diseases.
ALBPS | PA
Overview
Corporate Details
- ISIN(s):
- FR0012816825 (+4 more)
- LEI:
- 9695008GIE061NBGU106
- Country:
- France
- Address:
- 14 AVENUE DE L'OPERA, 75001 PARIS
- Website:
- https://www.biophytis.com/en/
Description
Biophytis S.A. is a clinical-stage biotechnology company focused on developing therapeutics to slow degenerative processes associated with aging and improve longevity. The company's primary strategy is centered on treating diseases that impair mobility. Its lead drug candidate, BIO101, is being advanced in late-stage clinical development for multiple age-related conditions. A key program is the SARA Phase 3 trial, the first-ever pivotal study for the treatment of sarcopenia (age-related muscle loss). Additionally, BIO101 is being evaluated in the OBA Phase 2 clinical trial for addressing muscle wasting in patients with obesity. The company aims to preserve muscle function and enhance functional outcomes for patients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-03-08 07:00 |
Biophytis presented the potential of RuvembriTM in the treatment of Duchenne Mu…
|
English | 201.3 KB | ||
| 2024-03-08 07:00 |
Biophytis a présenté le potentiel de RuvembriTM dans le traitement de la dystro…
|
French | 200.7 KB | ||
| 2024-02-22 07:00 |
"Live healthier longer" - Publication of a book on the medicine and science of …
|
English | 187.7 KB | ||
| 2024-02-22 07:00 |
« Vivre longtemps en bonne santé » - Publication d’un livre sur la médecine et …
|
French | 206.5 KB | ||
| 2024-01-04 07:00 |
Biophytis announces the publication of the results of its COVA phase 2-3 study …
|
English | 183.9 KB | ||
| 2024-01-04 07:00 |
Biophytis annonce la publication des résultats de son étude de phase 2-3 COVA d…
|
French | 201.1 KB | ||
| 2023-12-29 07:00 |
Biophytis announces the drawing of the fourth tranche of ORNANE under the 2021 …
|
English | 124.2 KB | ||
| 2023-12-29 07:00 |
Biophytis annonce le tirage de la quatrième tranche d'ORNANE dans le cadre du c…
|
French | 123.9 KB | ||
| 2023-12-11 07:00 |
Biophytis announces its participation in several conferences in Europe and the …
|
English | 184.2 KB | ||
| 2023-12-11 07:00 |
Biophytis annonce sa participation à plusieurs conférences en Europe et aux Eta…
|
French | 189.2 KB | ||
| 2023-12-04 07:00 |
Biophytis and the University of Liège explore the potential of Sarconeos (BIO10…
|
English | 213.2 KB | ||
| 2023-12-04 07:00 |
Biophytis et l’Université de Liège explorent le potentiel de Sarconeos (BIO101)…
|
French | 220.2 KB | ||
| 2023-11-27 07:00 |
Biophytis appoints Yann Meunier and Bernard Lévy to its Scientific Advisory Boa…
|
English | 187.7 KB | ||
| 2023-11-27 07:00 |
Biophytis nomme Yann Meunier et Bernard Lévy à son comité scientifique
|
French | 194.6 KB | ||
| 2023-11-20 07:00 |
Biophytis announces the success of its capital increase with preferential subs…
|
English | 216.0 KB |
Automate Your Workflow. Get a real-time feed of all Biophytis S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Biophytis S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Biophytis S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-11-22 | N/A | Other | Buy | 8,443,190 | 79,365.99 EUR |
| 2020-12-16 | N/A | Other | Sell | 500,000 | 499,000.00 EUR |
| 2020-12-16 | N/A | Other | Other | 313,417 | N/A |
| 2020-04-30 | N/A | Other | Other | 2,955,701 | 177,342.06 EUR |
Peer Companies
